Tilray Brands, Inc.
TLRY Nasdaq Medicinal Chemicals & Botanical Products Financials FY2017โFY2026
Last close ยท Oct 23, 2026
$2.81
4.1%What Tilray Brands, Inc. does
No business description yet.
- Legal name
- Tilray Brands, Inc.
- Fiscal year ends
- May 31, 2026
- Latest annual report
- 10-K ยท Jul 28, 2026
- Accession ยท CIK
- 0001437749-26-024698
0001731348
Revenue and margins
Tilray Brands, Inc. had $915M of revenue in fiscal 2026, up 11.5% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was โ in fiscal 2026, โ of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Tilray Brands, Inc. returned โ to shareholders in fiscal 2026. The diluted share count rose 25.6%.
Balance sheet
Cash, debt and the ratios that show how comfortably Tilray Brands, Inc. can carry it.
| Fiscal year end | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash and short-term investments | $416M | $449M | $261M | $256M | $231M |
| Debt incl. finance leases | $204M | $23.4M | $63.1M | $53.0M | $254M |
| Debt / equity | 0.0x | 0.0x | 0.0x | 0.0x | 0.1x |
| Interest coverage | โ15.4x | โ29.4x | โ3.5x | โ55.2x | โ2.1x |
| Current ratio | 2.9x | 1.8x | 2.3x | 2.5x | 2.2x |
| Quick ratio | 2.0x | 1.3x | 1.4x | 1.5x | 1.4x |
| Total assets | $5.4B | $4.3B | $4.2B | $2.1B | $2.3B |
| Total liabilities | $1.0B | $977M | $778M | $585M | $733M |
| Shareholders' equity | $4.4B | $3.3B | $3.4B | $1.5B | $1.6B |
| Net debt (โ = net cash) | โ$212M | โ$425M | โ$197M | โ$203M | $22.7M |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โPlanโ marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
โ
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8โ9 is strong, 0โ2 weak.
| Test | FY17 | FY18 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Net income is positive | โ | โ | โ | โ | โ | โ | โ | โ |
| Cash from operations is positive | โ | โ | โ | โ | โ | โ | โ | โ |
| Return on assets rose | โ | โ | โ | โ | โ | โ | โ | โ |
| Cash from operations exceeds net income | โ | โ | โ | โ | โ | โ | โ | โ |
| Debt fell relative to assets | โ | โ | โ | โ | โ | โ | โ | โ |
| Current ratio rose | โ | โ | โ | โ | โ | โ | โ | โ |
| Share count didn't rise | โ | โ | โ | โ | โ | โ | โ | โ |
| Gross margin rose | โ | โ | โ | โ | โ | โ | โ | โ |
| Revenue rose relative to assets | โ | โ | โ | โ | โ | โ | โ | โ |
| F-score | โ / 3 | โ / 5 | โ / 3 | 3 / 9 | 5 / 9 | 7 / 9 | 5 / 9 | 2 / 9 |
| Accruals ratio | โ | โ3.3% | โ0.4% | โ5.2% | โ29.9% | โ5.0% | โ66.5% | โ2.4% |
| Altman Z'' | โ | โ8.06 | 3.20 | 3.88 | 0.12 | 2.90 | โ11.01 | โ3.61 |
8 years of figures
Amounts in USD. Hover a ratioโs name for its definition.
| Fiscal year | FY17 | FY18 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $12.6M | $20.5M | $43.1M | $628M | $627M | $789M | $821M | $915M |
| Gross profit | $2.7M | $11.4M | $14.3M | $117M | $147M | $223M | $241M | $260M |
| Research and development | $1.1M | $3.2M | $5.9M | $1.5M | $0.7M | $0.6M | $0.3M | $0.4M |
| Operating income | โ$7.0M | โ$7.5M | โ$57.8M | โ$610M | โ$1.4B | โ$175M | โ$2.3B | โ$63.0M |
| Interest expense | $0.8M | $0.7M | $5.7M | $39.7M | $46.6M | $49.3M | $41.3M | $29.9M |
| Pretax income | โ$7.9M | โ$7.8M | โ$72.2M | โ$441M | โ$1.5B | โ$249M | โ$2.3B | โ$88.1M |
| Income tax | โ | โ | โ$4.5M | โ$6.5M | โ$7.2M | โ$26.6M | โ$121M | $17.1M |
| Net income | โ$7.9M | โ$7.8M | โ$67.7M | โ$477M | โ$1.5B | โ$245M | โ$2.2B | โ$121M |
| Diluted EPS | โ$0.11 | โ$0.10 | โ$0.82 | โ$0.99 | โ$2.35 | โ$3.30 | โ$24.56 | โ$1.09 |
| Diluted shares | 0.08B | 0.08B | 0.08B | 0.48B | 0.62B | 0.07B | 0.09B | 0.11B |
| Cash flow | ||||||||
| Cash from operations | โ$3.3M | โ$6.0M | โ$46.2M | โ$177M | $7.9M | โ$30.9M | โ$94.6M | โ$69.1M |
| Capital expenditure | $0.5M | $10.9M | $50.2M | $34.1M | $20.8M | $29.2M | $32.9M | โ |
| Free cash flow | โ$3.8M | โ$16.9M | โ$96.4M | โ$211M | โ$12.9M | โ$60.2M | โ$128M | โ |
| Depreciation and amortization | $2.0M | $1.9M | $3.6M | $155M | โ | โ | โ | โ |
| Stock-based compensation | $0.1M | $0.1M | $21.0M | $36.0M | $39.6M | $31.8M | $24.3M | $45.9M |
| Acquisitions | โ | โ | โ | โ$0.3M | $26.7M | $60.6M | $18.1M | $53.7M |
| Balance sheet | ||||||||
| Cash and short-term investments | $7.5M | $2.3M | $488M | $416M | $449M | $261M | $256M | $231M |
| Total debt | โ | $9.4M | $213M | $204M | $23.4M | $18.0M | $7.2M | $129M |
| Finance lease liabilities | โ | โ | โ | โ | โ | $45.0M | $45.9M | $125M |
| Current assets | โ | $12.4M | $884M | $804M | $773M | $678M | $689M | $792M |
| Current liabilities | โ | $50.2M | $401M | $280M | $433M | $299M | $280M | $358M |
| Inventory | โ | $7.4M | $256M | $246M | $201M | $252M | $271M | $301M |
| Property and equipment, net | โ | $40.0M | $651M | $587M | $430M | $558M | $568M | $680M |
| Goodwill | โ | โ | $2.8B | $2.6B | $2.0B | $2.0B | $752M | $752M |
| Intangible assets | โ | $0.9M | $1.6B | $1.3B | $974M | $915M | $21.4M | $42.8M |
| Total assets | โ | $53.9M | $6.0B | $5.4B | $4.3B | $4.2B | $2.1B | $2.3B |
| Total liabilities | โ | $58.8M | $1.6B | $1.0B | $977M | $778M | $585M | $733M |
| Preferred stock | โ | โ | โ | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $2.5M | โ$4.9M | $4.5B | $4.4B | $3.3B | $3.4B | $1.5B | $1.6B |
| Margins | ||||||||
| Gross margin | 21.1% | 55.4% | 33.1% | 18.6% | 23.4% | 28.3% | 29.3% | 28.4% |
| Operating margin | โ55.7% | โ36.5% | โ134.1% | โ97.1% | โ218.4% | โ22.1% | โ277.9% | โ6.9% |
| EBITDA margin | โ40.3% | โ27.5% | โ125.8% | โ72.5% | โ | โ | โ | โ |
| Net margin | โ62.3% | โ38.0% | โ157.0% | โ75.9% | โ231.6% | โ31.1% | โ266.3% | โ13.3% |
| FCF margin | โ30.1% | โ82.3% | โ223.6% | โ33.6% | โ2.1% | โ7.6% | โ15.5% | โ |
| Returns | ||||||||
| Return on capital | โ | โ262.4% | โ1.1% | โ11.5% | โ37.4% | โ4.3% | โ142.9% | โ3.3% |
| Return on capital employed | โ | โ201.2% | โ1.0% | โ11.8% | โ35.4% | โ4.5% | โ127.2% | โ3.2% |
| Return on equity | โ311.8% | โ | โ1.5% | โ10.8% | โ37.7% | โ7.2% | โ88.3% | โ7.8% |
| Return on assets | โ | โ14.5% | โ1.1% | โ8.3% | โ29.8% | โ5.7% | โ69.5% | โ5.5% |
| Return on tangible equity | โ311.8% | โ | โ332.7% | โ99.4% | โ436.1% | โ47.2% | โ296.4% | โ14.8% |
| Growth | ||||||||
| Revenue growth | โ | 62.4% | โ | 1,356.9% | โ0.2% | 25.8% | 4.1% | 11.5% |
| Share count change | โ | 0.0% | โ | 479.7% | 28.4% | โ88.0% | 19.9% | 25.6% |
| Financial health | ||||||||
| Debt / equity | โ | โ | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x | 0.1x |
| Interest coverage | โ9.1x | โ10.8x | โ10.2x | โ15.4x | โ29.4x | โ3.5x | โ55.2x | โ2.1x |
| Current ratio | โ | 0.2x | 2.2x | 2.9x | 1.8x | 2.3x | 2.5x | 2.2x |
| Quick ratio | โ | 0.1x | 1.6x | 2.0x | 1.3x | 1.4x | 1.5x | 1.4x |
| Capital allocation | ||||||||
| Capex / revenue | 3.9% | 53.1% | 116.4% | 5.4% | 3.3% | 3.7% | 4.0% | โ |
| Stock comp / revenue | 0.7% | 0.7% | 48.7% | 5.7% | 6.3% | 4.0% | 3.0% | 5.0% |
| Quality scores | ||||||||
| Piotroski F-score | โ | โ | โ | 3.0 | 5.0 | 7.0 | 5.0 | 2.0 |
| Altman Z'' | โ | โ8.1 | 3.2 | 3.9 | 0.1 | 2.9 | โ11.0 | โ3.6 |
| Accruals ratio | โ | โ3.3% | โ0.4% | โ5.2% | โ29.9% | โ5.0% | โ66.5% | โ2.4% |
Source: SEC EDGAR XBRL filings (CIK 0001731348). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only โ not investment advice. Check the original filings before relying on any figure.
